Breast Cancer Update: A CME Audio Series and Activity

STATMENT OF NEED / TARGET AUDIENCE
Breast cancer is one of the most rapidly evolving fields in medical oncology. Published results from a plethora of ongoing clinical trials lead to the continuous emergence of new therapeutic agents and changes in the indications for existing treatments. In order to offer optimal patient care — including the option of clinical trial participation — the practicing medical oncologist must be well-informed of these advances.

To bridge the gap between research and patient care, Breast Cancer Update utilizes one-on-one discussions with leading oncology investigators. By providing access to the latest research developments and expert perspectives, this CME program assists medical oncologists in the formulation of up-to-date clinical management strategies.

Issue 1, 2002 consists of discussions with three oncology leaders on a variety of issues pertinent to breast cancer. These topics include fulvestrant (an estrogen receptor downregulator), the current data on first-line hormonal therapy for metastatic breast cancer, the use and development of capecitabine (an oral fluoropyrimidine), algorithms for the assessment of HER2 status, and the current clinical applications and on-going trials of trastuzumab.

EDUCATIONAL OBJECTIVES
Upon completion of this activity, participants should be able to:

• Describe the mechanism of action and clinical trial results of fulvestrant, the estrogen
  receptor downregulator
• Review the current first-line data on hormonal treatment of metastatic disease
• Review the development and clinical use of the oral fluoropyrimidine, capecitabine in breast cancer treatment
• Review decision algorithms for assessment of HER2 status in breast cancer patients and identify the current clinical applications and on-going trials of trastuzumab

ACCREDITATION STATEMENT
This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of the Postgraduate Institute for Medicine and NL Communications, Inc. The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians and takes responsibility for the content, quality and scientific integrity of this CME activity.

DESIGNATION STATEMENT
The Postgraduate Institute for Medicine designates this educational activity for a maximum of 3 hours in category 1 credit toward the AMA Physician's Recognition Award. Each physician should claim only those hours of credit that he/she actually spent in the activity.

FACULTY DISCLOSURE STATEMENTS
Postgraduate Institute for Medicine has a conflict of interest policy that requires course faculty to disclose any real or apparent commercial financial affiliations related to the content of their presentations/materials. It is not assumed that these financial interests or affiliations will have an adverse impact on faculty presentations; they are simply noted in this supplement to fully inform participants.

Home · Search